# lncTAC

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lnctac

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.lnctac.com
- Latest round: Series A (Jun 26, 2026)
- Investors on record: 6

## About

Established in 2021 and based in Chengdu, China, Chengdu Lingtai Krypton Biotechnology Co., Ltd, trading as lncTAC, is a biotech company that focuses on research and development of lncRNA (long non-coding RNA) drugs. The founder and chairman of this company, Prof. Xu Song, is a PhD from the Peking Union Medical College of China and a postdoctoral fellow at Yale University. Mr. Lihua Ding, Co-founder and CEO, has 30 years of experience in the pharmaceutical industry. In June 2026, lncTAC raised a series A+ funding led by Panlin Capital, with participation from IMEik, Riverhead Capital and Huafang Capital, Legend Capital.

The company develops its own biotechnology, including lncTAC® and UNAST® technologies. UNAST® technology is a nucleic acid drug stabilization platform, while lncTAC® technology is an extrahepatic targeted delivery platform.

The company generates revenue by providing lncRNA-based nucleic acid drugs.

The company will focus on accelerating the critical process of lncRNA from validation to realization.

## Funding rounds

- Series A, Jun 26, 2026 — Lapam Capital
- Series A, Jun 26, 2026 — Legend Capital, Panlin Capital, Riverhead Capital, Huafang Capital, IMEik

## Investors

- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A
- Legend Capital — Series A
- Panlin Capital (https://capitalatlas.ai/funds/panlin-capital) — Series A
- Riverhead Capital (https://capitalatlas.ai/funds/riverhead-capital) — Series A
- Huafang Capital (https://capitalatlas.ai/funds/huafang-capital) — Series A
- IMEik — Series A